Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1147706 | 0.99 | HDAC3 (0.42) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL1147534 | 0.87 | HDAC3 (0.41) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL1147723 | 0.84 | HTT (0.43) | HDAC3HDAC1HDAC2HDAC6SMN1; SMN2 | |
| SCHEMBL1310492 | 0.82 | SMN1; SMN2 (0.41) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL1147699 | 0.79 | SMN1; SMN2 (0.42) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL1147790 | 0.78 | ALPI (0.43) | SMN1; SMN2KDM4EALDH1A1TSHRMAPT | |
| Hydrochloric Acid SCHEMBL1147805 | 0.78 | GAA (0.47) | KDM4EALDH1A1MAPTLMNA | |
| Hydrochloric Acid SCHEMBL1147695 | 0.70 | OPRK1 (0.39) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL1310609 | 0.69 | HTT (0.45) | HDAC3HDAC1HDAC2HDAC6SMN1; SMN2 | |
| SCHEMBL1056733 | 0.69 | MAOB (0.44) | SMN1; SMN2KDM4EALDH1A1HKDC1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058437-B2 | (Pyrroloquinoxalinyl) pyrazinecarbohydrazide-oxalic acid co-crystal for treatment of cancer and other diseases | NOVELIX PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | claimed |
| US-20110034473-A1 | NOVEL (PYRROLOQUINOXALINYL) PYRAZINECARBOHYDRAZIDE-OXALIC ACID CO-CRYSTAL FOR TREATMENT OF CANCER AND OTHER DISEASES | NOVELIX PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | US | claimed |
| EP-2276490-A1 | NOVEL (PYRROLOQUINOXALINYL) PYRAZINECARBOHYDRAZIDE-OXALIC ACID CO-CRYSTAL FOR TREATMENT OF CANCER AND OTHER DISEASES | Novelix Pharmaceuticals, Inc. (US) | 2011-01-26 | — | — | EP | claimed |
| WO-2009126743-A1 | NOVEL (PYRROLOQUINOXALINYL) PYRAZINECARBOHYDRAZIDE-OXALIC ACID CO-CRYSTAL FOR TREATMENT OF CANCER AND OTHER DISEASES | NOVELIX PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | WO | claimed |
| US-8058437-B2 | (Pyrroloquinoxalinyl) pyrazinecarbohydrazide-oxalic acid co-crystal for treatment of cancer and other diseases | NOVELIX PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058437-B2 | (Pyrroloquinoxalinyl) pyrazinecarbohydrazide-oxalic acid co-crystal for treatment of cancer and other diseases | NOVELIX PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110275646-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110034473-A1 | NOVEL (PYRROLOQUINOXALINYL) PYRAZINECARBOHYDRAZIDE-OXALIC ACID CO-CRYSTAL FOR TREATMENT OF CANCER AND OTHER DISEASES | NOVELIX PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034473-A1 | NOVEL (PYRROLOQUINOXALINYL) PYRAZINECARBOHYDRAZIDE-OXALIC ACID CO-CRYSTAL FOR TREATMENT OF CANCER AND OTHER DISEASES | NOVELIX PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| EP-2276490-A1 | NOVEL (PYRROLOQUINOXALINYL) PYRAZINECARBOHYDRAZIDE-OXALIC ACID CO-CRYSTAL FOR TREATMENT OF CANCER AND OTHER DISEASES | Novelix Pharmaceuticals, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-2276490-A1 | NOVEL (PYRROLOQUINOXALINYL) PYRAZINECARBOHYDRAZIDE-OXALIC ACID CO-CRYSTAL FOR TREATMENT OF CANCER AND OTHER DISEASES | Novelix Pharmaceuticals, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009126743-A1 | NOVEL (PYRROLOQUINOXALINYL) PYRAZINECARBOHYDRAZIDE-OXALIC ACID CO-CRYSTAL FOR TREATMENT OF CANCER AND OTHER DISEASES | NOVELIX PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009126743-A1 | NOVEL (PYRROLOQUINOXALINYL) PYRAZINECARBOHYDRAZIDE-OXALIC ACID CO-CRYSTAL FOR TREATMENT OF CANCER AND OTHER DISEASES | NOVELIX PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034473-A1 | NOVEL (PYRROLOQUINOXALINYL) PYRAZINECARBOHYDRAZIDE-OXALIC ACID CO-CRYSTAL FOR TREATMENT OF CANCER AND OTHER DISEASES | PDXK, OTC, XDH | HDAC3 3812/4885HDAC1 1425/4885HDAC2 1551/4885 |
| US-20110275646-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | VEGFA, TEK, LIPG | HDAC3 3355/4885HDAC1 3195/4885HDAC2 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.